scholarly journals Incidence rate of symptomatic venous thromboembolic disease in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort

2013 ◽  
Vol 11 (1) ◽  
pp. 16 ◽  
Author(s):  
Fernando Vázquez ◽  
María Posadas-Martínez ◽  
Jimena Vicens ◽  
Fernán González Bernaldo de Quirós ◽  
Diego Giunta
Amyloid ◽  
2016 ◽  
Vol 23 (3) ◽  
pp. 184-187 ◽  
Author(s):  
María Adela Aguirre ◽  
Bruno Rafael Boietti ◽  
Elsa Nucifora ◽  
Patricia Beatriz Sorroche ◽  
Fernán González Bernaldo de Quirós ◽  
...  

Author(s):  
Fernando Javier Vázquez ◽  
Maria Florencia Grande-Ratti ◽  
Maria Elena Zapiola ◽  
Diego Giunta ◽  
Maria Lourdes Posadas-Martinez

Medwave ◽  
2021 ◽  
Vol 21 (11) ◽  
pp. e002068-e002068
Author(s):  
María Lourdes Posadas-Martínez ◽  
Felipe Torres Gómez ◽  
Daniela Mezzarobba ◽  
Natalia Schutz ◽  
Jesica Ruberto ◽  
...  

Objective We aim to evaluate factors associated with the recurrence of thromboembolic episodes among patients with a first episode of venous thromboembolic disease during anticoagulation treatment and at least one year after treatment suspension. Methods A prospective cohort of patients with a first episode of deep vein thrombosis confirmed by Doppler ultrasound and initiated anticoagulation treatment. Participants were registered in the Institutional Registry of Thromboembolic Disease between June 2015 and March 2019. Patients with cancer, with permanent inferior vena cava filter implant, and those who refused to participate or did not provide informed consent were excluded. All patients were evaluated within treatment at 30 days and at least one year after the suspension of anticoagulation with a D-dimer study and an ultrasound. All patients were evaluated for recurrence, bleeding (major and minor), and death. Results A total of 304 patients were recruited during the study period. Seventy-three percent were female, and the median age was 80 years. The rate of recurrence rate during anticoagulation treatment was 5% (N = 16/303; 95% confidence interval: 3 to 8), and 5% during post-suspension follow-up (N = 11/202; 95%CI: 3 to 9). The overall bleeding rate was 13% (N = 39; 95%CI: 9 to 17), and 5% for major bleeding. Patients who recurred had higher basal D-dimer mean, higher neutrophils and monocytes, and a higher prevalence of age-adjusted D-dimer ratio greater than 0.5 before discontinuation. In addition, they more frequently had complete leg involvement by ultrasound and received a shorter treatment. Conclusions Although some baseline and pre-suspension parameters had a higher recurrence incidence, statistical significance was not reached, probably due to small statistical power and a short-term follow-up.


1990 ◽  
Vol 63 (01) ◽  
pp. 016-023 ◽  
Author(s):  
A M H P van den Bessekaar ◽  
J Meeuwisse-Braun ◽  
R M Bertina

SummaryFive different APTT reagents, two amidolytic anti-ITa assays, one amidoiytic anti-Xa assay, and one coagulometric anti-Xa/ anti-IIa assay were used to assess the effect of heparin in patients treated for venous thromboembolic disease. Good correlations were observed between lug-transformed APYE> determined with the various reagents (correlation coefficients: 0.92-0.96).Nevertheless there were important differences in the slopes of the lines of relationship between the APTT reagents.Good correlations were observed between the anti-Xa and anti-IIa assay results (correlation coefficients: 0.92-0.97). However, the amidolytic anti-Xa activity was significantly higher (p <0.001) than the two amidolytic anti-IIa activities. Less good correlations were observed between the log-transformed APTTs and the anti-Xa or anti-IIa activities (correlation coefficients: 0.64-0.78). The correlations were improved by transforming the APTT into APTT-ratio, i.e. the ratio of the patient’s APTT to the same patient’s APTT after removal of heparin from the plasma sample by means of ECTEOLA-cellulose treatment. The correlation coefficients of log (AFTT-ratio) with anti-Xa or anti-IIa ranged from 0.76 to 0.87.For both APTT and amidolytic heparin assay, the response to in vitro heparin was different from the response to ex vivo heparin.Therefore, equivalent therapeutic ranges should be assessed by using ex vivo samples rather than in vitro heparin. Because of the response differences between the APTT reagents, it is not adequate to define a therapeutic range for heparin therapy without specification of the reagent.


2018 ◽  
Vol 2 (12) ◽  
Author(s):  
Nifosì Lorenzo ◽  
Zuccarello Mariateresa ◽  
Nifosì Antonio Fabrizio ◽  
Hervas Saus Vanessa ◽  
Nifosì Gianfilippo

Sign in / Sign up

Export Citation Format

Share Document